LINKÖPING, Sweden, March 14, 2025 – AMRA Medical is muscling up for the 2025 Muscular Dystrophy Association’s Clinical and Scientific Conference (MDA…
Medical Research
AMRA presents new findings on chronic kidney disease and muscle composition at ICFSR 2025
LINKÖPING, Sweden, March 12, 2025 –We’re pleased to share that AMRA Medical—led by Markus Karlsson, PhD, and colleagues from Linköping and Lund Universities—will…
Pilot Study Demonstrates that AMRA’s Longitudinal Muscle Assessment Methodology is Feasible in Liver Transplant (LT) Candidates
LINKÖPING, Sweden, February 19, 2025 – A recent collaborative pilot project – led by Lisa VanWagner, MD, MSc of the University of Texas…
New study to be presented at the EASL-SLD summit shows that muscle composition predicts adverse outcomes in 5-year follow-up of patients with chronic liver disease, but not baseline fibrosis stage.
LINKÖPING, Sweden, January 22, 2025 –The 2025 EASL-SLD Summit – which runs from January 23-25th in beautiful Estoril, Portugal – brings together healthcare…
AMRA’s MRI assessments provide a unique understanding of weight loss in obesity
AMRA’s MRI-based biomarkers, including proprietary z-scores, offer a groundbreaking solution, providing researchers with a unique understanding of the nature and impact of these changes. By precisely measuring muscle volume and fat infiltration (an indicator of muscle quality), AMRA’s technology uncovers the hidden dynamics of weight loss, empowering the development of more effective therapies.
Latest AMRA Medical Research in Muscle & Nerve Demonstrates The Utility of MRI-based Biomarkers In Inflammatory Myopathies
The recent study details the use of fat-referenced volumetric muscle composition measurements as reliable biomarkers of disease progression and treatment response in sporadic inclusion body myositis, building upon AMRA’s increasing expertise in the neuromuscular disease space